Clinical Trials
394
Trial Phases
6 Phases
Drug Approvals
12
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (361 trials with phase data)• Click on a phase to view related trials
A Study of Oral E1018 in Healthy Adult Participants
- Conditions
- MalariaHealthy Participants
- Interventions
- Drug: E1018Drug: Placebo
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06854042
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population
- Conditions
- Sleep Initiation and Maintenance DisordersPregnancy
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 861
- Registration Number
- NCT06744673
- Locations
- 🇺🇸
Eisai Trial Site #1, Nutley, New Jersey, United States
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT06602258
- Locations
- 🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Bradenton Research Center, Bradenton, Florida, United States
A Study of E2086 in Healthy Adult Participants
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06481488
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
- Conditions
- Narcolepsy Type 1 (NT1)
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06462404
- Locations
- 🇺🇸
SDS Clinical Trials, Santa Ana, California, United States
🇺🇸PharmaDev Clinical Research, Miami, Florida, United States
🇺🇸Sleep Practioners, LLC, Macon, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 72
- Next
News
Aurobindo Pharma Secures Multiple FDA Approvals for Generic Drug Portfolio Expansion
Aurobindo Pharma Limited has received FDA approval for multiple generic drug formulations, including critical medications for cardiovascular, neurological, and gastrointestinal conditions.
LEAP-001 Trial: Lenvatinib and Pembrolizumab Combination Fails to Improve Survival in Advanced Endometrial Cancer
The Phase III LEAP-001 trial evaluated lenvatinib plus pembrolizumab versus chemotherapy as a first-line treatment for advanced or recurrent endometrial cancer.
Lenvatinib Plus Ifosfamide/Etoposide Fails to Significantly Improve Progression-Free Survival in Relapsed Osteosarcoma
A phase II study (OLIE) found that adding lenvatinib to ifosfamide/etoposide did not significantly improve progression-free survival (PFS) in pediatric and young adult patients with relapsed osteosarcoma.